Abstract Objective To investigate the mutation rate of the RAS gene and its clinical significance in children with acute lymphoblastic leukemia. Methods A retrospective analysis was performed on the medical data of 120 children with newly diagnosed acute lymphoblastic leukemia, who were admitted to the Third Affiliated Hospital of Zhengzhou University from January 2015 to January 2020 and underwent next-generation sequencing. The clinical and molecular features were analyzed. The impact of RAS gene mutation on the overall survival rate was evaluated in these children. Results Among the 120 children, 35 (29.2%) had RAS gene mutation, 30 (25.0%) had KRAS gene mutation, and 5 (4.2%) had both NRAS and KRAS gene mutations. All NRAS mutations and 71% (25/35) of KRAS mutations were located at the 12th and 13th codons. RAS gene mutation was detected in 35 (33.3%) out of 105 children with B-lineage acute lymphoblastic leukemia, but it was not detected in those with acute T lymphocyte leukemia. Of all the children, 11 (9.2%) were lost to follow-up, and among the 109 children followed up, 16 (14.7%) died. The children with RAS gene mutation had a significantly lower 2-year overall survival rate than those without RAS gene mutation (P<0.05). The prognosis of children with RAS gene mutation combined with WT1 overexpression and WBC>50×109/L at diagnosis was worse (P<0.05). Conclusions RAS gene mutation is commonly observed in children with B-lineage acute lymphoblastic leukemia and may have an adverse effect on prognosis.
YAO Yan-Ling,WANG Xi-Ge,ZHAO Xue-Lian et al. Detection of RAS gene mutation and its clinical significance in children with acute lymphoblastic leukemia[J]. CJCP, 2022, 24(3): 309-313.
YAO Yan-Ling,WANG Xi-Ge,ZHAO Xue-Lian et al. Detection of RAS gene mutation and its clinical significance in children with acute lymphoblastic leukemia[J]. CJCP, 2022, 24(3): 309-313.
Scheidig AJ, Burmester C, Goody RS. The pre-hydrolysis state of p21ras in complex with GTP: new insights into the role of water molecules in the GTP hydrolysis reaction of ras-like proteins[J]. Structure, 1999, 7(11): 1311-1324. PMID: 10574788. DOI: 10.1016/s0969-2126(00)80021-0.
Lübbert M, Mirro JJ, Miller CW, et al. N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis[J]. Blood, 1990, 75(5): 1163-1169. PMID: 2407301. DOI: 10.1182/blood.V75.5.1163.1163.
Dunna NR, Vuree S, Anuradha C, et al. NRAS mutations in de novo acute leukemia: prevalence and clinical significance[J]. Indian J Biochem Biophys, 2014, 51(3): 207-210. PMID: 25204082.
Wiemels JL, Zhang Y, Chang J, et al. RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia[J]. Leukemia, 2005, 19(3): 415-419. PMID: 15674422. DOI: 10.1038/sj.leu.2403641.
Perentesis JP, Bhatia S, Boyle E, et al. RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia[J]. Leukemia, 2004, 18(4): 685-692. PMID: 14990973. DOI: 10.1038/sj.leu.2403272.
Case M, Matheson E, Minto L, et al. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia[J]. Cancer Res, 2008, 68(16): 6803-6809. PMID: 18701506. DOI: 10.1158/0008-5472.CAN-08-0101.
von Lintig FC, Huvar I, Law P, et al. Ras activation in normal white blood cells and childhood acute lymphoblastic leukemia[J]. Clin Cancer Res, 2000, 6(5): 1804-1810. PMID: 10815901.
Zhang HH, Wang HS, Qian XW, et al. Ras pathway mutation feature in the same individuals at diagnosis and relapse of childhood acute lymphoblastic leukemia[J]. Transl Pediatr, 2020, 9(1): 4-12. PMID: 32154130. PMCID: PMC7036641. DOI: 10.21037/tp.2020.01.07.
Driessen EMC, van Roon EHJ, Spijkers-Hagelstein JAP, et al. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants[J]. Haematologica, 2013, 98(6): 937-944. PMID: 23403319. PMCID: PMC3669451. DOI: 10.3324/haematol.2012.067983.
Oshima K, Khiabanian H, da Silva-Almeida AC, et al. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia[J]. Proc Natl Acad Sci U S A, 2016, 113(40): 11306-11311. PMID: 27655895. PMCID: PMC5056035. DOI: 10.1073/pnas.1608420113.
[1]
Shaanxi Provincial Diagnosis and Treatment Center of Kawasaki Disease/Children's
Hospital of Shaanxi Provincial People's Hospital; Beijing Children's Hospital, Capital Medical University; Shanghai
Children's Medical Center; Children's Hospital of Shanghai Jiao Tong University; Xianyang Children's Hospital of
Shaanxi Province; Suzhou Children's Hospital, Suzhou University; Children's Hospital of Chongqing Medical University;
Expert Committee of Advanced Training for Pediatrician, China Maternal and Children's Health Association; Editorial Board of
Chinese Journal of Contemporary Pediatrics. Pediatric expert consensus on the application of glucocorticoids in Kawasaki disease[J]. CJCP, 2022, 24(3): 225-231.
